Vertex Pharmaceuticals Stock Today
VRTX Stock | USD 450.97 0.60 0.13% |
Performance0 of 100
| Odds Of DistressLess than 1
|
Vertex Pharmaceuticals is trading at 450.97 as of the 24th of November 2024; that is 0.13 percent increase since the beginning of the trading day. The stock's open price was 450.37. Vertex Pharmaceuticals has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Note, on October 8, 2024, Representative Ro Khanna of US Congress acquired under $15k worth of Vertex Pharmaceuticals's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 24th of July 1991 | Category Healthcare | Classification Health Care |
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 257.53 M outstanding shares of which 4.5 M shares are at this time shorted by private and institutional investors with about 4.51 trading days to cover. More on Vertex Pharmaceuticals
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Vertex Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
President CEO | MD FASN | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, SP 500 Index, Nasdaq 100, NASDAQ 100 Pre, ARCA Biotechnology, NASDAQ Composite, NASDAQ Health Care, Dow Jones Biotechnology, NASDAQ Composite Total, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Excise Tax Activities | Animal TestingCatholic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsVertex Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Vertex Pharmaceuticals' financial leverage. It provides some insight into what part of Vertex Pharmaceuticals' total assets is financed by creditors.
|
Vertex Pharmaceuticals (VRTX) is traded on NASDAQ Exchange in USA. It is located in 50 Northern Avenue, Boston, MA, United States, 02210 and employs 5,400 people. Vertex Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with a current market capitalization of 116.14 B. Vertex Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 257.53 M outstanding shares of which 4.5 M shares are at this time shorted by private and institutional investors with about 4.51 trading days to cover.
Vertex Pharmaceuticals currently holds about 9.77 B in cash with 3.54 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 38.06.
Check Vertex Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationVertex Pharmaceuticals shows a total of 257.53 Million outstanding shares. The majority of Vertex Pharmaceuticals outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Vertex Pharmaceuticals to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Vertex Pharmaceuticals. Please pay attention to any change in the institutional holdings of Vertex Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. On October 8, 2024, Representative Ro Khanna of US Congress acquired under $15k worth of Vertex Pharmaceuticals's common stock.
Check Vertex Ownership Details
Vertex Stock Institutional Holders
Instituion | Recorded On | Shares | |
Wellington Management Company Llp | 2024-06-30 | 4.1 M | |
Amundi | 2024-06-30 | 3.5 M | |
Norges Bank | 2024-06-30 | 3.4 M | |
Loomis, Sayles & Company Lp | 2024-06-30 | 3.1 M | |
Massachusetts Financial Services Company | 2024-09-30 | 2.9 M | |
Bank Of America Corp | 2024-06-30 | 2.6 M | |
Ubs Asset Mgmt Americas Inc | 2024-09-30 | 2.4 M | |
Legal & General Group Plc | 2024-06-30 | 2.4 M | |
Hhg Plc | 2024-06-30 | 2.4 M | |
Capital World Investors | 2024-09-30 | 26.8 M | |
Vanguard Group Inc | 2024-09-30 | 23.2 M |
Vertex Pharmaceuticals Historical Income Statement
Vertex Stock Against Markets
Vertex Pharmaceuticals Corporate Management
Jonathan JD | Executive Officer | Profile | |
Stephanie Franklin | Senior Officer | Profile | |
Mike Tirozzi | SVP Officer | Profile | |
Damian Esq | Chief VP | Profile | |
Ourania Tatsis | Ex Officer | Profile |
Additional Tools for Vertex Stock Analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.